Trade Catalyst Pharmaceuticals - CPRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 21.09 |
| Open | 21.01 |
| 1-Year Change | 53.81% |
| Day's Range | 20.81 - 21.08 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 21, 2024 | 21.05 | -0.08 | -0.38% | 21.13 | 21.15 | 20.80 |
| Nov 20, 2024 | 21.09 | -0.38 | -1.77% | 21.47 | 21.50 | 21.01 |
| Nov 19, 2024 | 21.32 | 0.62 | 3.00% | 20.70 | 21.32 | 20.70 |
| Nov 18, 2024 | 20.75 | 0.10 | 0.48% | 20.65 | 21.12 | 20.47 |
| Nov 15, 2024 | 20.53 | -0.97 | -4.51% | 21.50 | 21.50 | 20.37 |
| Nov 14, 2024 | 21.62 | -0.99 | -4.38% | 22.61 | 22.65 | 21.47 |
| Nov 13, 2024 | 22.74 | -0.30 | -1.30% | 23.04 | 23.44 | 22.74 |
| Nov 12, 2024 | 22.99 | -0.30 | -1.29% | 23.29 | 23.67 | 22.94 |
| Nov 11, 2024 | 23.37 | -0.65 | -2.71% | 24.02 | 24.05 | 23.15 |
| Nov 8, 2024 | 23.86 | 0.47 | 2.01% | 23.39 | 24.20 | 23.29 |
| Nov 7, 2024 | 23.18 | -0.88 | -3.66% | 24.06 | 24.15 | 22.97 |
| Nov 6, 2024 | 22.67 | -0.01 | -0.04% | 22.68 | 23.04 | 22.51 |
| Nov 5, 2024 | 21.89 | 0.39 | 1.81% | 21.50 | 21.98 | 21.36 |
| Nov 4, 2024 | 21.68 | 0.02 | 0.09% | 21.66 | 21.90 | 21.25 |
| Nov 1, 2024 | 21.83 | 0.16 | 0.74% | 21.67 | 22.18 | 21.48 |
| Oct 31, 2024 | 21.74 | 0.36 | 1.68% | 21.38 | 21.89 | 21.13 |
| Oct 30, 2024 | 21.51 | -0.14 | -0.65% | 21.65 | 21.84 | 21.43 |
| Oct 29, 2024 | 21.70 | 0.05 | 0.23% | 21.65 | 22.09 | 21.50 |
| Oct 28, 2024 | 21.80 | 0.48 | 2.25% | 21.32 | 22.00 | 21.32 |
| Oct 25, 2024 | 21.41 | -0.04 | -0.19% | 21.45 | 21.87 | 21.35 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Pharmaceuticals Company profile
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Catalyst Pharmaceuticals Inc revenues increased 18% to $140.8M. Net income decreased 47% to $39.5M. Revenues reflect Revenues increase of 16% to $138M. Net income was offset by Selling, general and adminis - Balancing increase of 14% to $45.2M (expense), reasear increase of 3% to $15.3M (expense), Other income, net decrease of 52% to $282K (income).
Equity composition
Common Stock $.001 Par, 4/11, 100M auth., 21,654,680 issd. Insiders own 22.54%. IPO 8/11/06, 3,350,000 shares @ $6 per share by First Albany Capital Inc. and Stifel, Nicolaus & Company, Incorporated. 9/08, P.O of 1.5M shares.
| Industry: | Biopharmaceuticals |
355 Alhambra Circle
Suite 801
CORAL GABLES
FLORIDA 33134
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com